# ProAgio

Source: https://onco.cc/drugs/proagio/  
OnCo record `proagio` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ProAgio is a protein drug from ProDa BioTech that targets an integrin receptor found on tumour blood vessels and the support cells around tumours. It is in an early trial with gemcitabine in triple-negative breast cancer that has spread.

## Summary

ProAgio is developed by ProDa BioTech and described in the registry as an anti-alpha-v-beta-3 integrin cytotoxin. The phase 1/2 trial NCT06460298 tests rising doses and then an expansion dose of ProAgio with gemcitabine in metastatic triple-negative breast cancer, with 51 participants planned.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline
- Modality: Protein cytotoxin (anti-integrin)
- Mechanism: Described in its ClinicalTrials.gov record as an anti-alpha-v-beta-3 integrin cytotoxin.

## Sources

- ClinicalTrials.gov: NCT06460298: https://clinicaltrials.gov/study/NCT06460298

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- companies: [ProDa BioTech](https://onco.cc/companies/proda-biotech/)
- trials: [ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct06460298/)

---
JSON: https://onco.cc/api/v1/entities/proagio.json